Vincera Pharma

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic PDX mouse models across several tumor types VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic PDX mouse models across several tumor types

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an α v β 3 small molecule drug conjugate (SMDC) in advanced solid tumors

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced four poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held virtually and at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023.

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's management team will present the company's corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

VIP236 is a first-in-class α V β 3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

Vincerx's proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzumab ozogamicin)

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Received Orphan Drug Designation for enitociclib; continue to focus on priority indications

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced three poster presentations at the upcoming 64th American Society of Hematology (ASH) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from December 10-13, 2022.

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

Continue to execute on priority indications for VIP152; recently issued the INN enitociclib

Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation

Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress

Chardan analyst Matthew Barcus lowered the price target on Vincerx Pharma Inc (NASDAQ: VINC) to $4 from $11 and kept a Buy rating on the shares.  The company announced a strategic update to focus on its Phase Ib development of lead program VIP152 in double-hit diffuse.

Analysts Cuts Price Target On This Small Cap But Remain Bullish

Prioritizing Phase 1b VIP152 studies to focus on double-hit DLBCL and CLL

Vincerx Pharma Provides Key Strategic Update

Company to present poster on VIP152 at upcoming European Hematology Association Annual Meeting

Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update

VIP152 demonstrates antitumor responses in preclinical models of gynecologic malignancies

Vincerx Pharma Presents Preclinical and Preliminary Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Gynecologic Malignancies at the American Association for Cancer Research (AACR) Annual Meeting 2022

Dosed first patient in VIP152 and pembrolizumab combination arm of study VNC-152-101

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

PALO ALTO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.

Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022

PALO ALTO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx's management team will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

VIP236 is a first-in-class anticancer agent, optimized using Vincerx's proprietary modular bioconjugation platform to target aggressive tumors

Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers

PALO ALTO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the first patient has been dosed in the Company's Phase 1 dose-escalation study of VIP152 in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or Richter Syndrome (RS).

Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome

VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of disease

Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting

PALO ALTO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the European Commission has granted Orphan Drug Designation to VIP152, the Company's PTEFb/CDK9 inhibitor, for the treatment of diffuse large B-cell lymphoma (DLBCL).

Vincerx Pharma Receives Orphan Drug Designation from European Commission for VIP152 for the Treatment of Diffuse Large B-Cell Lymphoma

PALO ALTO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it will host a key opinion leader (KOL) webinar to discuss the data presented on the Company's lead asset, VIP152, in chronic lymphocytic leukemia (CLL) and diffuse large B-Cell lymphoma (DLBCL) at the 63rd American Society of Hematology (ASH) Annual Meeting on Saturday, December 11, 2021 at 7:30pm Eastern Standard Time.

Vincerx Pharma Hosting Key Opinion Leader Webinar on VIP152 Data Presented at the American Society of Hematology Annual Meeting

Advancing Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors

Vincerx Pharma Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

PALO ALTO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that two abstracts related to the Company's selective PTEFb/CDK9 inhibitor, VIP152, program have been accepted for presentation at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, to be held December 11-14, 2021 in Atlanta, GA. The following abstracts were published today and are now available on the ASH website at www.hematology.org.

News for Vincera Pharma Stock (VINC)